Charles Schwab
AVBP icon

Charles Schwab’s ArriVent BioPharma AVBP Stock Holding History

Charles Schwab’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Buy
294,224
+35,452
+14% +$1.05M ﹤0.01% 2135
2026
Q1 		$5.97M Buy
258,772
+8,184
+3% +$185K ﹤0.01% 2329
2025
Q4 		$5.04M Buy
250,588
+7,102
+3% +$148K ﹤0.01% 2453
2025
Q3 		$4.49M Buy
243,486
+55,284
+29% +$1.09M ﹤0.01% 2489
2025
Q2 		$4.1M Sell
188,202
-8,292
-4% -$172K ﹤0.01% 2413
2025
Q1 		$3.63M Sell
196,494
-9,885
-5% -$242K ﹤0.01% 2406
2024
Q4 		$5.5M Buy
206,379
+4,011
+2% +$115K ﹤0.01% 2297
2024
Q3 		$4.76M Buy
202,368
+122,641
+154% +$2.78M ﹤0.01% 2398
2024
Q2 		$1.48M Buy
79,727
+1,967
+3% +$35.1K ﹤0.01% 2794
2024
Q1 		$1.39M Buy
+77,760
New +$1.57M ﹤0.01% 2699

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab's AVBP Position: Q2 2026 in Review

Charles Schwab increased its ArriVent BioPharma (AVBP) stake by 14% in Q2 2026, buying an estimated $1.05M and bringing the position to 294,224 shares worth $10.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2135.

Charles Schwab first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Charles Schwab held 294,224 shares of ArriVent BioPharma worth $10.2M as of Q2 2026.
  • Charles Schwab bought 35,452 ArriVent BioPharma shares in Q2 2026, an estimated $1.05M.
  • ArriVent BioPharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2135 holding.
  • Charles Schwab first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.